Portal de Periódicos da CAPES

Herpes Zoster

2011; American College of Physicians; Volume: 154; Issue: 5 Linguagem: Inglês

10.7326/0003-4819-154-5-201103010-01003

1539-3704

Jennifer Fisher Wilson,

Bartonella species infections research

In the Clinic1 March 2011Herpes ZosterDeborah Cotton, MD, MPH, Darren Taichman, MD, Sankey Williams, MD, and Jennifer F. WilsonDeborah Cotton, MD, MPHSearch for more papers by this author, Darren Taichman, MDSearch for more papers by this author, Sankey Williams, MDSearch for more papers by this author, and Jennifer F. WilsonSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-5-201103010-01003 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Herpes zoster, a painful skin rash that is commonly known as shingles, occurs in approximately 1 million people in the United States annually (1). Herpes zoster can develop in anyone who has had varicella (chickenpox). About 95% of the adult U.S. population has had varicella and thus can have herpes zoster. Approximately one third of persons will have an episode of herpes zoster, and the frequency increases with increasing age. Herpes zoster occurs when the varicella zoster virus, which causes both varicella and herpes zoster, is reactivated from its latent state in the dorsal root or cranial nerve ganglia and ...References1. Schmader KE, Dworkin RH. Natural history and treatment of herpes zoster. J Pain. 2008;9:S3-9. [PMID: 18166460] Google Scholar2. Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70 Suppl 1:S111-8. [PMID: 12627498] Google Scholar3. Rimland D, Moanna A. Increasing incidence of herpes zoster among Veterans. Clin Infect Dis. 2010;50:1000-5. [PMID: 20178416] Google Scholar4. LaRussa P, Steinberg SP, Shapiro E, Vazquez M, Gershon AA. Viral strain identification in varicella vaccinees with disseminated rashes. Pediatr Infect Dis J. 2000;19:1037-9. [PMID: 11099082] Google Scholar5. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19:916-23. [PMID: 11115716] Google Scholar6. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30; quiz CE2-4. [PMID: 18528318] Google Scholar7. Hurley LP, Harpaz R, Daley MF, Crane LA, Beaty BL, Barrow J, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis. 2008;197 Suppl 2:S216-23. [PMID: 18419400] Google Scholar8. Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55:1499-507. [PMID: 17908055] Google Scholar9. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al; Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84. [PMID: 15930418] Google Scholar10. Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis. 1998;178 Suppl 1:S109-12. [PMID: 9852987] Google Scholar11. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, et al; Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010;152:545-54. [PMID: 20439572] Google Scholar12. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305:160-6. [PMID: 21224457] Google Scholar13. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2010. Ann Intern Med. 2010;152:36-9. [PMID: 20048270] Google Scholar14. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44:1280-8. [PMID: 17443464] Google Scholar15. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145:317-25. [PMID: 16954357] Google Scholar16. Hurley LP, Lindley MC, Harpaz R, Stokley S, Daley MF, Crane LA, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152:555-60. [PMID: 20439573] Google Scholar17. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis. 2008;197 Suppl 2:S224-7. [PMID: 18419401] Google Scholar18. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005;5:68. [PMID: 15960856] Google Scholar19. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis. 2005;191:2002-7. [PMID: 15897984] Google Scholar20. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect. 2005;133:245-53. [PMID: 15816149] Google Scholar21. Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA. Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis. 2008;197 Suppl 2:S196-9. [PMID: 18419397] Google Scholar22. National Comprehensive Cancer Network; guidelines. Accessed at www.nccn.org/index.asp on January 13, 2011. Google Scholar23. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906-17. [PMID: 18753647] Google Scholar24. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer. 2009;115:229-32. [PMID: 19090004] Google Scholar25. Kim DH, Kumar D, Messner HA, Minden M, Gupta V, Kuruvilla J, et al. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant. 2008;22:770-9. [PMID: 18707605] Google Scholar26. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2008;83:472-6. [PMID: 18266207] Google Scholar27. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737-44. [PMID: 19224750] Google Scholar28. Sauerbrei A, Wutzler P. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen. J Clin Microbiol. 2006;44:3094-7. [PMID: 16954232] Google Scholar29. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321:794-6. [PMID: 11009518] Google Scholar30. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997;13:327-31. [PMID: 9204652] Google Scholar31. McKendrick MW, McGill JI, Wood MJ. Lack of effect of acyclovir on postherpetic neuralgia. BMJ. 1989;298:431. [PMID: 2495051] Google Scholar32. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-9. [PMID: 17976353] Google Scholar33. Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999;179:9-15. [PMID: 9841816] Google Scholar34. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med. 1995;123:89-96. [PMID: 7778840] Google Scholar35. Shafran SD, Tyring SK, Ashton R, Decroix J, Forszpaniak C, Wade A, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol. 2004;29:248-53. [PMID: 15018852] Google Scholar36. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546-53. [PMID: 7492102] Google Scholar37. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000;9:863-9. [PMID: 10031393] Google Scholar38. Huff JC, Bean B, Balfour HH Jr, Laskin OL, Connor JD, Corey L, et al. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988;85:84-9. [PMID: 3044099] Google Scholar39. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J. 1989;102:93-5. [PMID: 2648213] Google Scholar40. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed). 1986;293:1529-32. [PMID: 3099943] Google Scholar41. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996;22:341-7. [PMID: 8838194] Google Scholar42. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009:CD006866. [PMID: 19370655] Google Scholar43. Gilden DH, Beinlich BR, Rubinstien EM, Stommel E, Swenson R, Rubinstein D, et al. Varicella-zoster virus myelitis: an expanding spectrum. Neurology. 1994;44:1818-23. [PMID: 7936229] Google Scholar44. Peterslund NA. Herpes zoster associated encephalitis: clinical findings and acyclovir treatment. Scand J Infect Dis. 1988;20:583-92. [PMID: 3222675] Google Scholar45. Cobo M, Foulks GN, Liesegang T, Lass J, Sutphin J, Wilhelmus K, et al. Observations on the natural history of herpes zoster ophthalmicus. Curr Eye Res. 1987;6:195-9. [PMID: 3493883] Google Scholar46. Cobo Cobo LM, Foulks GN, Liesegang T, Lass J, Sutphin JE, Wilhelmus K, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986;93:763-70. [PMID: 3488532] Google Scholar47. Herbort CP, Buechi ER, Piguet B, Zografos L, Fitting P. High-dose oral acyclovir in acute herpes zoster ophthalmicus: the end of the corticosteroid era. Curr Eye Res. 1991;10 Suppl:171-5. [PMID: 1864091] Google Scholar48. Hoang-Xuan T, Büchi ER, Herbort CP, Denis J, Frot P, Thénault S, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99:1062-70; discussion 1070-1. [PMID: 1495785] Google Scholar49. Liesegang TJ. Varicella zoster viral disease. Mayo Clin Proc. 1999;74:983-98. [PMID: 10918864] Google Scholar50. Dworkin RH, Barbano RL, Tyring SK, Betts RF, McDermott MP, Pennella-Vaughan J, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain. 2009;142:209-17. [PMID: 19195785] Google Scholar51. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology. 2005;65:444-7. [PMID: 16087911] Google Scholar52. van Wijck AJ, Opstelten W, Moons KG, van Essen GA, Stolker RJ, Kalkman CJ, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet. 2006;367:219-24. [PMID: 16427490] Google Scholar53. He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008:CD005582. [PMID: 18254083] Google Scholar54. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896-900. [PMID: 8114860] Google Scholar55. Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376-83. [PMID: 8702088] Google Scholar56. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-9. [PMID: 17976353] Google Scholar57. Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J Infect Dis. 1994;169:91-4. [PMID: 8277202] Google Scholar58. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1996;17:53-80. [PMID: 8789689] Google Scholar59. Kuroiwa Y, Furukawa T. Hemispheric infarction after herpes zoster ophthalmicus: computed tomography and angiography. Neurology. 1981;31:1030-2. [PMID: 6973708] Google Scholar60. Eidelberg D, Sotrel A, Horoupian DS, Neumann PE, Pumarola-Sune T, Price RW. Thrombotic cerebral vasculopathy associated with herpes zoster. Ann Neurol. 1986;19:7-14. [PMID: 3004319] Google Scholar61. Nagel MA, Cohrs RJ, Mahalingam R, Wellish MC, Forghani B, Schiller A, et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology. 2008;70:853-60. [PMID: 18332343] Google Scholar62. Cheung WC, Yuen KY, Chang CM, Cheng KP. Herpes zoster associated encephalitis in dialysis patients. J Infect. 1991;23:169-74. [PMID: 1753116] Google Scholar63. Ormerod LD, Larkin JA, Margo CA, Pavan PR, Menosky MM, Haight DO, et al. Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS. Clin Infect Dis. 1998;26:34-45; discussion 46-7. [PMID: 9455507] Google Scholar64. Garweg J, Böhnke M. Varicella-zoster virus is strongly associated with atypical necrotizing herpetic retinopathies. Clin Infect Dis. 1997;24:603-8. [PMID: 9145733] Google Scholar65. Blumenkranz MS, Culbertson WW, Clarkson JG, Dix R. Treatment of the acute retinal necrosis syndrome with intravenous acyclovir. Ophthalmology. 1986;93:296-300. [PMID: 3703498] Google Scholar66. Palay DA, Sternberg P Jr, Davis J, Lewis H, Holland GN, Mieler WF, et al. Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. Am J Ophthalmol. 1991;112:250-5. [PMID: 1882936] Google Scholar67. Crapotta JA, Freeman WR. Visual outcome in acute retinal necrosis [Letter]. Retina. 1994;14:382-3. [PMID: 7817036] Google Scholar68. Galindez OA, Sabates NR, Whitacre MM, Sabates FN. Rapidly progressive outer retinal necrosis caused by varicella zoster virus in a patient infected with human immunodeficiency virus. Clin Infect Dis. 1996;22:149-51. [PMID: 8824984] Google Scholar69. Schliefer K, Gümbel HO, Rockstroh JK, Spengler U. Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. Clin Infect Dis. 1999;29:684-5. [PMID: 10530469] Google Scholar70. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Risk of cancer after herpes zoster: a population-based study. N Engl J Med. 1982;307:393-7. [PMID: 6979711] Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByRisk of severe herpes zoster infection in patients with polycystic kidney disease: A nation‐wide cohort study with propensity score matching analysisHigher risk of herpes zoster in stroke patientsSevere mental disorders following anti-retroviral treatment in a patient on peritoneal dialysis: A case report and literature reviewHerpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the LiteratureRandomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adultsMood Disorders and Risk of Herpes Zoster in 2 Population-Based Case-Control Studies in Denmark and the United KingdomOral Infectious DiseasesHerpes Zoster in the Older AdultMalignancy risks after herpes zoster: Hospital-based matched cohort studyA systematic review and meta-analysis on herpes zoster and the risk of cardiac and cerebrovascular eventsHerpes zoster as a marker of occult cancer: A systematic review and meta-analysisHospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortalityPrevention and screeningResearch HighlightsViral infections in acute graft-versus-host disease: A review of diagnostic and therapeutic approachesHerpes zosterLumbosacral and Thoracic RadiculopathiesHerpes Zoster: Diagnostic, Therapeutic, and Preventive ApproachesImmunization in End-Stage Renal Disease: Opportunity to Improve OutcomesDysesthesia of the mandibleRecurrence of SIADH With Localized Herpes Zoster InfectionA Systematic Review of the Cost Effectiveness of Herpes Zoster VaccinationClinical practice guideline of acupuncture for herpes zosterExternal eye disease and the oculocutaneous disordersPostprocedural inflammatory inferior alveolar neuropathy: an important differential diagnosisHerpes Zoster Vaccination in People Aged 50–59 Years 1 March 2011Volume 154, Issue 5Page: ITC3-1KeywordsAntiviral therapyAntiviralsCentral nervous systemChildrenImmune systemLesionsRashesVaccinesVaricella zoster virus ePublished: 1 March 2011 Issue Published: 1 March 2011 CopyrightCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...